Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
02/2001
02/14/2001EP1075518A2 Human transcriptional regulator molecules
02/14/2001EP1075508A2 Enzymatic nucleic acids molecules which modulate the expressions and/or replication of hepatitis c virus
02/14/2001EP1075496A1 Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
02/14/2001EP1075495A1 Gprw receptor
02/14/2001EP1075494A2 Compounds and methods for modulating nonclassical cadherin-mediated functions
02/14/2001EP1075492A1 Melanocortin 1 receptor selective compounds
02/14/2001EP1075491A2 Pth2 receptor selective compounds
02/14/2001EP1075490A1 Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use
02/14/2001EP1075488A1 Protein purification by ion exchange chromatography
02/14/2001EP1075282A1 Peg-lhrh analog conjugates
02/14/2001EP1075281A2 Polyol-ifn-beta conjugates
02/14/2001EP1075280A2 Hemoglobine-haptoglobin complexes for targeted durg delivery
02/14/2001EP1075277A2 Methods for detecting and inhibiting angiogenesis
02/14/2001EP1075274A2 Immunomodulators for vaccines
02/14/2001EP1075273A2 Inhibiton of helicobacter pylori proliferation
02/14/2001EP1075272A1 Methods for treating diabetes by inhibiting gdf-8
02/14/2001EP1075271A2 Method of treating interstitial cystitis with recombinant heparin-binding epidermal growth factor-like growth factor (hb-egf)
02/14/2001EP1075270A1 Short peptides for treatment of neurological degenerative diseases
02/14/2001EP1075269A2 Anti-diarrheal and method for using the same
02/14/2001EP1075266A1 Hematopoietic stimulation
02/14/2001EP1075255A1 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof
02/14/2001EP1003577A4 Blood product delivery system
02/14/2001EP0968226A4 G-rich oligo aptamers and methods of modulating an immune response
02/14/2001EP0844874A4 METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ALPHA v BETA 5 MEDIATED ANGIOGENESIS
02/14/2001EP0799577B1 Peptide mixture and products thereof
02/14/2001EP0738280B1 Superactive vip antagonists
02/14/2001CN1284134A Methods of producing anti-angiogenic proteins: endostation, angiostation or restin, using pichia yeast expression system
02/14/2001CN1284130A Mutants of endostation, 'EM1' having ant-angiogenic activety and methods of use thereof
02/14/2001CN1284086A Conjugates useful in treatment of prostate cancer
02/14/2001CN1284084A Echinocandin derivatives, prepn. method and application as anti-fungal agents
02/14/2001CN1284083A Tumor antigen peptide derivatives
02/14/2001CN1284063A Compounds
02/14/2001CN1284060A Novel metalloproteinase inhibitors
02/14/2001CN1284058A Neuroprotective agents
02/14/2001CN1283997A Keratinocyte growth factor-2 formulations
02/14/2001CN1283695A Gene associated with esophagus cancer
02/14/2001CN1283694A Gene associated with esophagus cancer
02/14/2001CN1283693A Cell factor CKLF-HIA with functions of hematopoietic stimulation and immunoregulation and its variant CKLF-HIB
02/14/2001CN1283631A Gene recombination human platelet factor No.4 and its new usage
02/14/2001CN1283629A Antineoplastic gancoderma mycelium-glucoprotein composition and its application and preparing process
02/14/2001CN1283628A Extract of shark cartilage and its preparing process
02/14/2001CN1283622A 6-hydroxy-3(4-[2-(piperidine-1-group)oxyethyl group]phenoxy)-2-(4-methoxy phenyl) benzo[b] thiophene hydrochloride salt
02/14/2001CN1283508A Beautifying cosmetics series for treating red blood trace on face
02/14/2001CN1283447A Locally-used weight reducing face-care compsns.
02/14/2001CN1061992C Colony stimulating factor for recombination of human granulocytes and medicinal compsn thereof
02/14/2001CN1061991C Schistosome vaccine peptide NO.3
02/14/2001CN1061990C Schistosome vaccine peptide No.1
02/13/2001USRE37053 Particles incorporating surfactants for pulmonary drug delivery
02/13/2001US6187993 Transgenic animals as model of psoriasis
02/13/2001US6187909 Amino acid sequences of receptor to neurologic regulators; antiinflammatory agents
02/13/2001US6187908 Tubby 2 polypeptides
02/13/2001US6187906 Methods to improve neural outcome
02/13/2001US6187905 Peptide compound which inhibits viral proteinases; viricides for hepatitis c, hepatitis g, and human gb viruses
02/13/2001US6187804 2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1 -hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid, salt or hydrolysable ester thereof for example, dry blended with an alkali metal carbonate or bicarbonate
02/13/2001US6187803 Treating allergic disease, autoimmune disease, immunodeficiency syndrome, inflammatory disease or eosinophilia by orally administering a histamine-added immunoglobulin and carrier; tablets, capsules
02/13/2001US6187800 Method for the prevention and treatment of mastitis
02/13/2001US6187771 Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
02/13/2001US6187756 Composition and methods for treatment of neurological disorders and neurodegenerative diseases
02/13/2001US6187752 Method for treating schizophrenia employing an ace inhibitor
02/13/2001US6187751 Biologically active peptide of ob protein
02/13/2001US6187750 Administering human growth hormone
02/13/2001US6187749 Methods for variation of chromatin condensation
02/13/2001US6187748 Treatment and prevention of hiv
02/13/2001US6187746 Pharmaceutical compositions based on dalfopristine and on quinupristine, and preparation thereof
02/13/2001US6187745 Co-administration of a pentosan polysulfate (pps) or a pharmaceutically acceptable salt thereof.
02/13/2001US6187744 Time-controlled superoxygenating compositions that comprise hemoglobin colloid and guanosine 3':5'-cyclic monophosphate (cyclic gmp) generating compounds
02/13/2001US6187743 Composition and method for enhancing wound healing
02/13/2001US6187742 Method for healing and repair of connective tissue attachment
02/13/2001US6187593 Methods for treating a fibrin encapsulated tumor using a fibrin specific monoclonal antibody and compositions used therein
02/13/2001US6187587 Nucleotide sequences; for diagnosis and treatment of related disorders
02/13/2001US6187586 Nucleotide sequence of compound which inhibits expression of human serine/threonine kinase involved in signal transduction; diagnosis, prophylaxis, and therapy of related diseases
02/13/2001US6187585 Oligonucleotide inhibition of epidermal growth factor receptor expression
02/13/2001US6187572 Decontaminating blood and cell cultures by mixing with a chemical radiation sensitizer which does not bind to the membrane, freezing or freeze-drying the mixture, then exposing to electromagnetic radiation
02/13/2001US6187564 Nucleotide sequences coding a fusion protein; for the proliferation, differentiation and activation of hematopoietic stem cells; for treatment of cancers; anticarcinogenic agents
02/13/2001US6187563 βIV-spectrin-polypeptides and nucleic acids encoding same
02/13/2001US6187562 Polynucleotides encoding human sphingosine Lyase
02/13/2001US6187561 Nucleotide sequence coding enzymatic polypeptide associated with charging molecule during translation; for detection of bactericides; for antibiotic prophylaxis before dental treatment; for prevention of infections; wound healing agents
02/13/2001US6187557 Nucleotide sequences coding modulator protein; for the diagnosis and treatment of defects in apotosis
02/13/2001US6187553 Eliminating physiological effects of heparin in blood mixture in blood recovery tube; preparing mixture of heparinase, trehalose and buffer, spray coat wall of tube, dry, remove oxygen, stopper, irradiate, add blood and allow to coagulate
02/13/2001US6187548 Detecting modulators of a human receptor polypeptide; expressing receptor polypeptide in cell, incubating modulator with cell expressing receptor polypeptide, monitor modulating activity
02/13/2001US6187545 Oligonucleotide sequences associated with the suppression of the activity of phosphenolpyruvate carboxykinase
02/13/2001US6187543 Method of screening a compound for its ability to enhance the ability of tristetraprolin to inhibit tumor necrosis factor
02/13/2001US6187533 Screening for genome adjustments associated with non-insulin dependent diabetes; obtaining nucleotide sequences from human, analyze nucleotide sequences for genome adjustment, presence of genome adjustment indicates genetic disorders
02/13/2001US6187345 Flutamide compositions and preparations
02/13/2001US6187344 Powdered pharmaceutical formulations having improved dispersibility
02/13/2001US6187334 Low methoxyl pectin, sodium alginates and acids, carrageenan and gellan gum
02/13/2001US6187330 Local delivery of angiogenic amounts of basic fibroblast growth factor or vascular endothelial growth factor.
02/13/2001US6187320 Which contain foreign dna elements in addition to the genome sequences necessary for the replication.
02/13/2001US6187312 Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of infectious diseases
02/13/2001US6187311 Engineered acarid allergen and process for producing the same
02/13/2001US6187308 Ameliorating an immune response disorder.
02/13/2001US6187307 Cancer immunotherapy with semi-allogeneic cells
02/13/2001US6187304 Effects of IFN-γ on cardiac hypertrophy
02/13/2001US6187287 Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
02/13/2001US6186148 Prevention of posterior capsular opacification
02/13/2001CA2315588A1 Use of antithrombin iii for the prophylaxis and therapy of diseases
02/13/2001CA2280314A1 Pulmonary surfactant formulation for instillation and for oral application
02/13/2001CA2192674C Methods for treating respiratory disease
02/13/2001CA2139358C Human growth hormone aqueous formulation
02/13/2001CA2127117C Dna encoding a human serotonin receptor (5-ht4b) and uses thereof